- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02424227
Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation (DART)
Circulating Donor-Derived Cell-free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a prospective, multicenter, observational study of kidney transplant subjects where blood specimens, intended for dd-cfDNA and other future research purposes, will be drawn after transplant periodically and also after the treatment of acute rejection up to 8 weeks post treatment. The blood samples and all relevant clinical data will be provided to CareDx scientists for laboratory assay of dd-cfDNA levels and correlation of dd-cfDNA levels with the clinical features of the subjects.
The primary objective of the study is to correlate circulating dd-cfDNA to clinical and sub-clinical acute rejection in renal allograft recipients. The secondary objective of the study is to correlate circulating dd-cfDNA to renal function, both serum creatinine and estimated glomerular filtration rate [eGFR]).
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35294
- University of Alabama, Birmingham
-
-
California
-
Los Angeles, California, Förenta staterna, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Förenta staterna, 90024
- University of California Los Angeles
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Indiana University
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21201
- University of Maryland
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55414
- University of Minnesota
-
-
Missouri
-
Saint Louis, Missouri, Förenta staterna, 63110
- Washington University
-
-
New York
-
New York, New York, Förenta staterna, 10032
- Columbia University
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- University of Pennsylvannia
-
Pittsburgh, Pennsylvania, Förenta staterna, 15213
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Fort Worth, Texas, Förenta staterna, 76104
- Baylor Research Institute
-
Temple, Texas, Förenta staterna, 76502
- Baylor Scott and White
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria
- Adult recipients (Age > 18 years )
- Both genders and all racial and ethnic groups
- Kidney transplant alone
- Both living and deceased donor transplants
- Primary and re-transplants. A total of 30 re-transplant recipients across all study sites will be eligible for enrollment. CareDx will notify all centers when this subset of enrollment has been met. Thereafter, all enrolled patients should be primary transplant recipients.
- Ability to come for follow-up and undergo biopsy (Performed in accordance to SOC)
- Ability to give written informed consent prior to study enrollment
Patients can be enrolled at any time; before or after transplantation and/or at time of outpatient or inpatient visits for workup of medical problems; e.g. at the time of a renal biopsy (regardless of elapsed time since post transplant) as specified in this study protocol.
Exclusion Criteria
- Pediatric recipients (Age < 18 years)
- Pregnant women
- Patients undergoing multi-organ transplants (e.g. kidney with pancreas or liver)
- Patients receiving donor organ from an identical twin
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Endast fall
- Tidsperspektiv: Blivande
Kohorter och interventioner
Grupp / Kohort |
---|
Kidney Transplant Recipients
Adult living and deceased donor kidney transplant recipients will be eligible to participate in this study.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Clinical T cell as well as antibody mediated acute rejection
Tidsram: Occurring within 12 months post transplant
|
Occurring within 12 months post transplant
|
Sub-clinical T cell as well as antibody mediated acute rejection
Tidsram: Occurring within 12 months post transplant
|
Occurring within 12 months post transplant
|
Composite of clinical and sub-clinical T cell as well as antibody mediated acute rejection
Tidsram: Occurring within 12 months post transplant
|
Occurring within 12 months post transplant
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
eGFR (estimated Glomerular Filtration Rate [mL/min]): will be derived from serum creatinine level, corrected for variables, using the CKD-RPI (Chronic Kidney Disease Epidemiology Collaboration) equation
Tidsram: 24 months
|
24 months
|
Renal allograft injury from BKV nephritis, CNI toxicity, acute pyeloenephrtiis and recurrent disease confirmed by renal histology
Tidsram: 24 months
|
24 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: James Yee, MD, CareDx
Publikationer och användbara länkar
Allmänna publikationer
- Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M; Banff meeting report writing committee. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014 Feb;14(2):272-83. doi: 10.1111/ajt.12590. Erratum In: Am J Transplant. 2015 Oct;15(10):2784. Rangel, Erika [corrected to Rangel, Erika B].
- De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, Neff NF, Okamoto J, Bernstein D, Weisshaar D, Quake SR, Khush KK. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014 Jun 18;6(241):241ra77. doi: 10.1126/scitranslmed.3007803.
- Lo YM. Transplantation monitoring by plasma DNA sequencing. Clin Chem. 2011 Jul;57(7):941-2. doi: 10.1373/clinchem.2011.166686. No abstract available.
- Snyder TM, Khush KK, Valantine HA, Quake SR. Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6229-34. doi: 10.1073/pnas.1013924108. Epub 2011 Mar 28.
- Code of Federal Regulations, Title 42 - Public Health, Part 493 - Laboratory Requirements, Subpart A - General Provisions, Sections 1, 2 & 3
- Hidestrand M, Tomita-Mitchell A, Hidestrand PM, Oliphant A, Goetsch M, Stamm K, Liang HL, Castleberry C, Benson DW, Stendahl G, Simpson PM, Berger S, Tweddell JS, Zangwill S, Mitchell ME. Highly sensitive noninvasive cardiac transplant rejection monitoring using targeted quantification of donor-specific cell-free deoxyribonucleic acid. J Am Coll Cardiol. 2014 Apr 1;63(12):1224-1226. doi: 10.1016/j.jacc.2013.09.029. Epub 2013 Oct 16. No abstract available.
- Sigdel TK, Vitalone MJ, Tran TQ, Dai H, Hsieh SC, Salvatierra O, Sarwal MM. A rapid noninvasive assay for the detection of renal transplant injury. Transplantation. 2013 Jul 15;96(1):97-101. doi: 10.1097/TP.0b013e318295ee5a.
- Sawinski DL, Mehta S, Alhamad T, Bromberg JS, Fischbach B, Aeschbacher T, Ghosh S, Shekhtman G, Dholakia S, Brennan DC, Poggio E, Bloom RD, Jordan SC. Association between dd-cfDNA levels, de novo donor specific antibodies, and eGFR decline: An analysis of the DART cohort. Clin Transplant. 2021 Sep;35(9):e14402. doi: 10.1111/ctr.14402. Epub 2021 Jul 14.
- Bromberg JS, Brennan DC, Poggio E, Bunnapradist S, Langone A, Sood P, Matas AJ, Mannon RB, Mehta S, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen DJ, Zaky ZS, Hiller D, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Bloom RD. Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. J Appl Lab Med. 2017 Nov 1;2(3):309-321. doi: 10.1373/jalm.2016.022731.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- SN-C-00006
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Mottagare av njurtransplantation
-
Abramson Cancer Center of the University of PennsylvaniaIndragenCancerpatienter som genomgår stamcellstransplantation (RCT of ACP for Transplant)
-
Novartis PharmaceuticalsAvslutad
-
Fayoum UniversityCairo UniversityHar inte rekryterat ännuSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Atara BiotherapeuticsRekryteringLymfoproliferativa störningar | Stamcellstransplantationskomplikationer | Komplikationer vid transplantation av fasta organ | Allogen hematopoetisk celltransplantation | Epstein-Barr Virus+ Associated Post-transplant lymfoproliferativ sjukdom (EBV+ PTLD)Förenta staterna, Österrike, Australien, Belgien, Kanada, Frankrike, Italien, Spanien, Storbritannien
-
Medical University of ViennaAvslutadSekundär hyperparatyreos | CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder | NjurersättningÖsterrike
-
Hans BahlmannLinkoeping UniversityRekryteringNjurcancer | Uretercancer | Andra specificerade störningar av njure och urinledare | Benign Neoplasm av Ureter | Calculus of Kidney and Ureter | Ureterisk reflux | Medfödd ureteranomali | Benign renal neoplasmSverige